Kaleido Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Kaleido Biosciences's estimated annual revenue is currently $855k per year.
- Kaleido Biosciences received $101.0M in venture funding in June 2018.
- Kaleido Biosciences's estimated revenue per employee is $25,909
- Kaleido Biosciences's total funding is $230.9M.
- Kaleido Biosciences's current valuation is $94.1M. (January 2022)
- Kaleido Biosciences has 33 Employees.
- Kaleido Biosciences grew their employee count by -73% last year.
Kaleido Biosciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kaleido Biosciences?
Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders. Kaleido's unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Learn more at https://kaleido.com/.keywords:N/A
Number of Employees
Employee Growth %
Kaleido Biosciences News
Microbiome-focused company, Kaleido Biosciences, in a filing with the US Securities and Exchange Commission (SEC) on Friday, announced its...
A few months after Flagship Pioneering spinout Kaleido Biosciences slashed 30 percent of its workforce, the company said it is shutting down...
Kaleido was formed in 2015 by Flagship Pioneering, a venture capital firm whose other microbiome portfolio companies include Seres Therapeutics...
LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the appointment of current Boa ...
LEXINGTON, Mass. - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Kaleido Biosciences Funding